This may point to the preferential killing of non-PB cancer-initiating cells, allowing PB cancer-initiating cells to survive and grow, lack of sufficient local drug concentration to effectively kill tumor cells, or rapid selection and emergence of drug-resistant variants due to absence of p53. This evidence concerns the gene TP53 and neoplasm.